(S)-3-(甲基磺酰基)吡咯烷 | 290328-57-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (S)-3-(甲基磺酰基)吡咯烷
• 中文别名: (S)-3-(甲磺酰基)吡咯烷
• 英文名称: (S)-3-(methylsulfonyl)pyrrolidine
• 英文别名: (3S)-3-methylsulfonylpyrrolidine
• CAS: 290328-57-3
• 化学式: C₅H₁₁NO₂S
• 分子量: 149.214
• InChiKey: XCEGFNRUBBVHJT-YFKPBYRVSA-N

物化性质

• 沸点：
  326.9±31.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (S)-3-(Methylsulfonyl)pyrrolidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (S)-3-(Methylsulfonyl)pyrrolidine
CAS number: 290328-57-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11NO2S
Molecular weight: 149.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-3-(甲基磺酰基)吡咯烷 在 sodium hexamethyldisilazane 作用下， 以 甲醇 、 乙醇 、 甲苯 为溶剂， 生成 methyl 7-fluoro-3-[[(3S)-3-methylsulfonylpyrrolidin-1-yl]methyl]-4-oxo-1-phenylquinoline-2-carboxylate
  参考文献：
  名称：

  Discovery of a novel series of 4-quinolone JNK inhibitors

  摘要：

  A novel series of highly selective JNK inhibitors based on the 4-quinolone scaffold was designed and synthesized. Structure based drug design was utilized to guide the compound design as well as improvements in the physicochemical properties of the series. Compound (13c) has an IC50 of 62/170 nM for JNK1/2, excellent kinase selectivity and impressive efficacy in a rodent asthma model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.10.066
• 作为产物：
  描述：

  (S)-benzyl 3-(methylthio)pyrrolidine-1-carboxylate 在 sodium tungstate (VI) dihydrate 、 palladium 10% on activated carbon 、 氢气 、 双氧水 作用下， 以 甲醇 、 水 为溶剂， 反应 49.0h， 生成 (S)-3-(甲基磺酰基)吡咯烷
  参考文献：
  名称：

  [EN] NOVEL HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE BCR-ABL INHIBITORS
  [FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES COMME INHIBITEURS DE LA TYROSINE KINASE BCR-ABL

  摘要：

  揭示了一种式（Ⅰ）的化合物或其药学上可接受的盐，其中所述的变量在此处描述。还揭示了一种制备化合物的方法，其药用组合物包括作为活性成分的相同化合物，使用这些组合物治疗各种疾病的方法，以及利用这些化合物制造药物以抑制ABL1、ABL2和相关嵌合蛋白的酶活性。

  公开号：

  WO2017186148A1

文献信息

• [EN] SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES<br/>[FR] DIHYDROPYRAZOLO[4,3-B]INDOLES SUBSTITUÉES DANS LES POSITIONS 1 ET 4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014039831A1

  公开（公告）日：2014-03-13

  Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein L, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

  本公开涉及式（1）的化合物及其药用盐，其中L、R1、R2、R3、R4、R5、R6和R7在规范中定义。本公开还涉及制备式1化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗与MetAP2相关的肥胖和相关疾病、紊乱和病况的用途。
• [EN] HER2 MUTATION INHIBITORS<br/>[FR] INHIBITEURS DE MUTATION HER2
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2022003575A1

  公开（公告）日：2022-01-06

  This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用可接受盐，其中L1、L2、R1、R2、R3和n如本文所定义。本发明还涉及包括这些化合物和盐的药物组合物，以及利用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。
• Near-Infrared Photoswitching of Azobenzenes under Physiological Conditions
  作者：Mingxin Dong、Amirhossein Babalhavaeji、Catherine V. Collins、Kareem Jarrah、Oleg Sadovski、Qiuyun Dai、G. Andrew Woolley

  DOI：10.1021/jacs.7b06471

  日期：2017.9.27

  physiological conditions. A fused dioxane ring and a methoxy substituent were used to place oxygen atoms in all four ortho positions, as well as two meta positions, relative to the azobenzene N═N double bond. This substitution pattern, together with a para pyrrolidine group, raises the pKa of the molecule so that it is protonated at physiological pH and absorbs at wavelengths >700 nm. This azobenzene derivative

  生物组织在700到900 nm之间的近红外光中显示出最小的吸光度，可以使光线深入穿透。在该生物光学窗口中经历光异构化的分子作为光药物开发的核心结构和化学生物学工具的组成是非常理想的。我们报告了系统设计，合成和测试的偶氮苯衍生物量身定制的单光子光开关与近红外光在生理条件下。相对于偶氮苯N ＝ N双键，使用稠合的二恶烷环和甲氧基取代基将氧原子置于所有四个邻位以及两个间位。此取代模式，有一起对吡咯烷基团提高了分子的p K a，使其在生理pH下被质子化，并在> 700 nm的波长处吸收。此偶氮苯衍生物被称为DOM偶氮，是用于在中性水溶液个月是稳定，进行反式-到-顺式与720nm的光控光，并热回复到稳定的反式与接近1秒的半衰期异构体。
• SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150225405A1

  公开（公告）日：2015-08-13

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

  本发明涉及公式1的化合物及其药学上可接受的盐，其中L，R1，R2，R3，R4，R5，R6和R7在说明书中有定义。本公开还涉及制备公式1化合物的材料和方法，包含它们的制药组合物，以及它们用于治疗肥胖和与MetAP2相关的疾病、障碍和病况的用途。
• [EN] HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1)<br/>[FR] COMPOSÉS D'AMINO PYRIDINE HALO-SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE DES PROGÉNITEURS HÉMATOPOÏÉTIQUES 1 (HPK1)
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2022226668A1

  公开（公告）日：2022-11-03

  The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.

  本申请涉及公式（I）的卤代杂环化合物或其药学上可接受的盐、溶剂或前药，以及包含这些化合物或药学上可接受的盐、溶剂或前药的组合物，以及在治疗可通过抑制HPK1来治疗的疾病、紊乱或情况方面的各种用途，例如癌症。